Oral Oncology
Volume 38, Issue 6 , Pages 532-542 , September 2002

Anticancer activity and mechanism of action of retinoids in oral and pharyngeal cancer

Received 22 October 2001 ,Accepted 29 October 2001.

References 

  1. World Cancer Research Fund in association with American Institute for Cancer Research . Food, nutrition and the prevention of cancer: a global perspective. Washington: The American Institute for Cancer Research; 1997;
  2. Vokes EE, Weichselbaum RR, Lippman SM, Hong WK. Head and neck cancer. N Engl J Med. 1993;328:184–194
  3. Muir C, Weiland L. Upper aerodigestiv tract cancers. Cancer. 1995;75:147–153
  4. Van der Waal I. Oral precancerous lesions—present knowledge. Deut Zahnartzl Z. 1992;47:860–864
  5. Braakhuis BJM, Tabor MPT, Leemans CR, van der Waal I, Snow, GB, Brakenhoff RH. Second primary tumors and field cancerization in oral and oropharyngeal cancer: molecular techniques provide new insights and definitions. Head Neck, 2001 (in press).
  6. Snow GB. Follow-up in patients treated for head and neck cancer (how frequent, how thorough and for how long?). Eur J Cancer. 1992;28:315–316
  7. Sporn MB, Roberts AB, Goodman DS. The retinoids. Biology, chemistry and medicine. 2nd ed.. New York: Raven Press; 1994;
  8. Kune GA, Kune S, Field B, Watson LF, Cleland H, Merenstein D, et al.  Oral and pharyngeal cancer, diet, smoking, alcohol, and serum vitamin A and beta-carotene levels: a case-control study in men. Nutr Cancer. 1993;20:61–70
  9. de Vries N, Snow GB. Relationships of vitamins A and E and beta-carotene serum levels to head and neck cancer patients with and without second primary tumors. Eur Arch Otorhinolaryngol. 1990;247:368–370
  10. Fontham ET. Protective dietary factors and lung cancer. Int J Epidemiol. 1990;19(1):S32–S42
  11. Graham S. Epidemiology of retinoids and cancer. J Natl Cancer Inst. 1984;73:1423–1428
  12. Gudas LJ, Sporn MB, Roberts AB. Cellular biology and biochemistry of the retinoids. In:  Sporn MB,  Roberts AB,  Goodman DS editor. The retinoids. Biology, chemistry and medicine. 2nd ed. New York: Raven Press; 1994;p. 443–520
  13. Costa SL, Paillaud E, Fages C, Rochette-Egly C, Plassat JL, Jouault H, et al.  Effects of a novel synthetic retinoid on malignant glioma in vitro: inhibition of cell proliferation, induction of apoptosis and differentiation. Eur J Cancer. 2001;37:520–530
  14. Hayashi K, Yokozaki H, Naka K, Yasui W, Lotan R, Tahara E. Overexpression of retinoic acid receptor beta induces growth arrest and apoptosis in oral cancer cell lines. Jpn J Cancer Res. 2001;92:42–50
  15. Sun SY, Yue P, Shroot B, Hong WK, Lotan R. Induction of apoptosis in human non-small cell lung carcinoma cells by the novel synthetic retinoid CD437. J Cell Physiol. 1997;173:279–284
  16. Schwartsmann G, Pinedo HM, Leyva A. Resistance of HL-60 promyelocytic leukemia cells to induction of differentiation and its reversal by combination treatment. Eur J Cancer Clin Oncol. 1987;23:739–743
  17. Strickland S, Mahdavi V. The induction of differentiation in teratocarcinoma stem cells by retinoic acid. Cell. 1978;15:393–403
  18. Hinds TS, West WL, Knight EM. Carotenoids and retinoids (a review of research, clinical, and public health applications). J Clin Pharmacol. 1997;37:551–558
  19. Semba RD. The role of vitamin A and related retinoids in immune function. Nutr Rev. 1998;56:S38–S48
  20. Blomhoff R, Green MH, Berg T, Norum KR. Transport and storage of vitamin, A. Science. 1990;250:399–404
  21. Edenberg HJ, Brown CJ, Carr LG, Ho WH, Hur MW. Alcohol dehydrogenase gene expression and cloning of the mouse chi-like ADH. Adv Exp Med Biol. 1991;284:253–262
  22. Duester G. Involvement of alcohol dehydrogenase, short-chain dehydrogenase/reductase, aldehyde dehydrogenase, and cytochrome P450 in the control of retinoid signaling by activation of retinoic acid synthesis. Biochemistry. 1996;35:12221–12227
  23. Rockley NL, Halley BA, Nelson EC. Identification of a decarboxylation product of retinoic acid. Biochim Biophys Acta. 1980;627:270–275
  24. Leo MA, Iida S, Lieber CS. Retinoic acid metabolism by a system reconstituted with cytochrome P-450. Arch. Biochem. Biophys. 1984;234:305–312
  25. Sass JO, Forster A, Bock KW, Nau H. Glucuronidation and isomerization of all-trans- and 13-cis-retinoic acid by liver microsomes of phenobarbital- or 3-methylcholanthrene-treated rats. Biochem. Pharmacol. 1994;47:485–492
  26. Eckhoff C, Collins MD, Nau H. Human plasma all-trans-, 13-cis- and 13-cis-4-oxoretinoic acid profiles during subchronic vitamin A supplementation (comparison to retinol and retinyl ester plasma levels). J Nutr. 1991;121:1016–1025
  27. Tang G, Russell RM. Formation of all-trans-retinoic acid and 13-cis-retinoic acid from all-trans-retinyl palmitate in humans. J Nutr Biochem. 1991;2:210–213
  28. Heyman RA, Mangelsdorf DJ, Dyck JA, Stein RB, Eichele G, Evans RM, et al.  9-cis retinoic acid is a high affinity ligand for the retinoid X receptor. Cell. 1992;68:397–406
  29. Levin AA, Sturzenbecker LJ, Kazmer S, Bosakowski T, Huselton C, Allenby G, et al.  9-cis retinoic acid stereoisomer binds and activates the nuclear receptor RXR alpha. Nature. 1992;355:359–361
  30. McCormick AM, Napoli JL, Schnoes HK, DeLuca HF. Isolation and identification of 5, 6-epoxyretinoic acid: a biologically active metabolite of retinoic acid. Biochemistry. 1978;17:4085–4090
  31. Skare KL, Schnoes HK, DeLuca HF. Biliary metabolites of all-trans-retinoic acid in the rat (isolation and identification of a novel polar metabolite). Biochemistry. 1982;21:3308–3317
  32. Thaller C, Eichele G. Isolation of 3,4-didehydroretinoic acid, a novel morphogenetic signal in the chick wing bud. Nature. 1990;345:815–819
  33. Roberts AB, Lamb LC, Sporn MB. Metabolism of all-trans-retinoic acid in hamster liver microsomes (oxidation of 4-hydroxy- to 4-keto-retinoic acid). Arch. Biochem. Biophys. 1980;199:374–383
  34. Leo MA, Lasker JM, Raucy JL, Kim CI, Black M, Lieber CS. Metabolism of retinol and retinoic acid by human liver cytochrome P450IIC8. Arch. Biochem. Biophys. 1989;269:305–312
  35. Ray WJ, Bain G, Yao M, Gottlieb DI. CYP26, a novel mammalian cytochrome P450, is induced by retinoic acid and defines a new family. J Biol Chem. 1997;272:18702–18708
  36. White JA, Beckett-Jones B, Guo YD, Dilworth FJ, Bonasoro J, Jones G. cDNA cloning of human retinoic acid-metabolizing enzyme (hP450RAI) identifies a novel family of cytochromes P450. J Biol Chem. 1997;272:18538–18541
  37. Marikar Y, Wang Z, Duell EA, Petkovich M, Voorhees JJ, Fisher GJ. Retinoic acid receptors regulate expression of retinoic acid 4-hydroxylase that specifically inactivates all-trans retinoic acid in human keratinocyte HaCaT cells. J Invest Dermatol. 1998;111:434–439
  38. Mangelsdorf DJ. Vitamin A receptors. Nutr Rev. 1994;52:S32–S44
  39. Mangelsdorf DJ, Umesono K, Evans RM. The retinoid receptors. In:  Sporn MB,  Roberts AB,  Goodman DS editor. The retinoids. Biology, chemistry and medicine. 2nd ed. New York: Raven Press; 1994;p. 319–349
  40. Leid M, Kastner P, Chambon P. Multiplicity generates diversity in the retinoic acid signalling pathways. Trends Biochem Sci. 1992;17:427–433
  41. Xu L, Glass CK, Rosenfeld MG. Coactivator and corepressor complexes in nuclear receptor function. Curr Opin Genet Dev. 1999;9:140–147
  42. Fanjul A, Dawson MI, Hobbs PD, Jong L, Cameron JF, Harvey E, et al.  The Ying-yang of RAR and AP-1: cancer treatment without overt toxicity. Nature. 1994;372:107–111
  43. Nagpal S, Athanikar J, Chandraratna RA. Separation of transactivation and AP1 antagonism functions of retinoic acid receptor alpha. J Biol Chem. 1995;270:923–927
  44. Kamei Y, Xu L, Heinzel T, Torchia J, Kurokawa R, Gloss B, et al.  A CBP integrator complex mediates transcriptional activation and AP-1 inhibition by nuclear receptors. Cell. 1996;85:403–414
  45. Braakhuis BJ, Klaassen I, van der Leede BM, Cloos J, Brakenhoff RH, Copper MP, et al.  Retinoid metabolism and all-trans retinoic acid-induced growth inhibition in head and neck squamous cell carcinoma cell lines. Br J Cancer. 1997;76:189–197
  46. Klaassen I, Brakenhoff RH, Smeets SJ, Snow GB, Braakhuis BJ. Enhanced turnover of all-trans-retinoic acid and increased formation of polar metabolites in head and neck squamous cell carcinoma lines compared with normal oral keratinocytes. Clin Cancer Res. 2001;7:1017–1025
  47. Muindi J, Frankel SR, Miller WH, Jakubowski A, Scheinberg DA, Young CW, et al.  Continuous treatment with all-trans retinoic acid causes a progressive reduction in plasma drug concentrations: implications for relapse and retinoid “resistance’ in patients with acute promyelocytic leukaemia. Blood. 1992;79:299–303
  48. Takatsuka J, Takahashi N, de Luca LM. Retinoic acid metabolism and inhibition of cell proliferation (an unexpected liaison). Cancer Res. 1996;56:675–678
  49. Klaassen I, Brakenhoff RH, Smeets SJ, Snow GB, Braakhuis BJ. Metabolism and growth inhibition of four retinoids in head and neck squamous normal and malignant cells. Br J Cancer. 2001;85:630–635
  50. Xu XC, Ro JY, Lee JS, Shin DM, Hong WK, Lotan R. Differential expression of nuclear retinoid receptors in normal, premalignant, and malignant head and neck tissues. Cancer Res. 1994;54:3580–3587
  51. Lotan R, Xu XC, Lippman SM, Ro JY, Lee JS, Lee JJ, et al.  Suppression of retinoic acid receptor-beta in premalignant oral lesions and its up-regulation by isotretinoin. N Engl J Med. 1995;332:1405–1410
  52. Hu L, Crowe DL, Rheinwald JG, Chambon P, Gudas LJ. Abnormal expression of retinoic acid receptors and keratin 19 by human oral and epidermal squamous cell carcinoma cell lines. Cancer Res. 1991;51:3972–3981
  53. Xu XC, Liu X, Tahara E, Lippman SM, Lotan R. Expression and up-regulation of retinoic acid receptor-beta is associated with retinoid sensitivity and colony formation in esophageal cancer cell lines. Cancer Res. 1999;59:2477–2483
  54. Sun SY, Kurie JM, Yue P, Dawson MI, Shroot B, Chandraratna RA, et al.  Differential responses of normal, premalignant, and malignant human bronchial epithelial cells to receptor-selective retinoids. Clin Cancer Res. 1999;5:431–437
  55. Oridate N, Esumi N, Lotan D, Hing WK, Rochette-Egly C, Chambon P, et al.  Implication of retinoic acid receptor gamma in squamous differentiation and response to retinoic acid in head and neck SqCC/Y1 squamous carcinoma cells. Oncogene. 1996;12:2019–2028
  56. Le Q, Dawson MI, Soprano DR, Soprano KJ. Modulation of retinoic acid receptor function alters the growth inhibitory response of oral SCC cells to retinoids. Oncogene. 2000;19:1457–1465
  57. Klaassen I, Brakenhoff RH, Smeets SJ, Snow GB, Braakhuis BJ. Expression of retinoic acid receptor gamma correlates with retinoic acid sensitivity and metabolism in head and neck squamous cell carcinoma cell lines. Int J Cancer. 2001;92:661–665
  58. Hill DL, Grubbs CJ. Retinoids and cancer prevention. Annu. Rev. Nutr. 1992;12:161–181
  59. Lippman SM, Parkinson DR, Itri LM, Weber RS, Schantz SP, Ota DM, et al.  13-cis-retinoic acid and interferon alpha-2a: effective combination therapy for advanced squamous cell carcinoma of the skin. J Natl Cancer Inst. 1992;84:235–241
  60. Lippman SM, Kavanagh JJ, Paredes-Espinoza M, Delgadillo-Madrueno F, Paredes-Casillas P, Hong WK, et al.  13-cis-retinoic acid plus interferon alpha-2a: highly active systemic therapy for squamous cell carcinoma of the cervix. J Natl Cancer Inst. 1992;84:241–245
  61. Pastorino U, Infante M, Maioli M, Chiesa G, Buyse M, Firket P, et al.  Adjuvant treatment of stage I lung cancer with high-dose vitamin A. J Clin Oncol. 1993;11:1216–1222
  62. Kakizuka A, Miller WH, Umesono K, Warrell RP, Frankel SR, Murty VV, et al.  Chromosomal translocation t(15;17) in human acute promyelocytic leukemia fuses RAR alpha with a novel putative transcription factor, PML. Cell. 1991;66:663–674
  63. Goddard AD, Borrow J, Freemont PS, Solomon E. Characterization of a zinc finger gene disrupted by the t(15;17) in acute promyelocytic leukemia. Science. 1991;254:1371–1374
  64. Martini R, Murray M. Participation of P450 3A enzymes in rat hepatic microsomal retinoic acid 4-hydroxylation. Archives of Biochemistry & Biophysics. 1993;303:57–66
  65. Rigas JR, Francis PA, Muindi JR, Kris MG, Huselton C, DeGrazia F, et al.  Constitutive variability in the pharmacokinetics of the natural retinoid, all-trans-retinoic acid, and its modulation by ketoconazole. J Natl Cancer Inst. 1993;85:1921–1926
  66. Rigas JR, Miller VA, Zhang ZF, Klimstra DS, Tong WP, Kris MG, et al.  Metabolic phenotypes of retinoic acid and the risk of lung cancer. Cancer Res. 1996;56:2692–2696
  67. Hong WK, Endicott J, Itri LM, Doos W, Batsakis JG, Bell R, et al.  13-cis-retinoic acid in the treatment of oral leukoplakia. N Engl J Med. 1986;315:1501–1505
  68. Lippman SM, Meyskens FL. Retinoids as anticancer agents. Prog Clin Biol Res. 1988;259:229–244
  69. Silverman S, Gorsky M, Lozada F. Oral leukoplakia and malignant transformation. A follow-up study of 257 patients. Cancer. 1984;53:563–568
  70. Schepman KP, van der Meij EH, Smeele LE, van der Waal I. Malignant transformation of oral leukoplakia (a follow-up study of a hospital-based population of 166 patients with oral leukoplakia from The Netherlands). Oral Oncol. 1998;34:270–275
  71. Shklar G, Flynn E, Szabo G, Marefat P. Retinoid inhibition of experimental lingual carcinogenesis (ultrastructural observations). J Natl Cancer Inst. 1980;65:1307–1316
  72. Lippman SM, Batsakis JG, Toth BB, Weber RS, Lee JJ, Martin JW, et al.  Comparison of low-dose isotretinoin with beta carotene to prevent oral carcinogenesis. N Engl J Med. 1993;328:15–20
  73. Issing WJ, Struck R, Naumann A. Long-term follow-up of larynx leukoplakia under treatment with retinyl palmitate. Head Neck. 1996;18:560–565
  74. Stich HF, Hornby AP, Mathew B, Sankaranarayanan R, Nair MK, Response of oral leukoplakias to the administration of vitamin A. Cancer Lett. 1988;40:93–101
  75. Lee JJ, Hong WK, Hittelman WN, Mao L, Lotan R, Shin DM, et al.  Predicting cancer development in oral leukoplakia: ten years of translational research. Clin Cancer Res. 2000;6:1702–1710
  76. Hong WK, Lippman SM, Itri LM, Karp DD, Lee JS, Byers RM, et al.  Prevention of second primary tumors with isotretinoin in squamous-cell carcinoma of the head and neck. N Engl J Med. 1990;323:795–801
  77. Benner SE, Pajak TF, Lippman SM, Earley C, Hong WK. Prevention of second primary tumors with isotretinoin in patients with squamous cell carcinoma of the head and neck (long-term follow-up). J Natl Cancer Inst. 1994;86:140–141
  78. van Zandwijk N, Dalesio O, Pastorino U, de Vries N, van Tinteren H. EUROSCAN, a randomized trial of vitamin A and N-acetylcysteine in patients with head and neck cancer or lung cancer. For the European Organization for Research and Treatment of Cancer Head and Neck and Lung Cancer Cooperative Groups. J Natl Cancer Inst. 2000;92:977–986
  79. Copper MP, Klaassen I, Teerlink T, Snow GB, Braakhuis BJ. Plasma retinoid levels in head and neck cancer patients (a comparison with healthy controls and the effect of retinyl palmitate treatment). Oral Oncol. 1999;35:40–44
  80. Bolla M, Lefur R, Ton Van J, Domenge C, Badet JM, Koskas Y, et al.  Prevention of second primary tumours with etretinate in squamous cell carcinoma of the oral cavity and oropharynx. Results of a multicentric double-blind randomised study. Eur J Cancer. 1994;30A:767–772
  81. Mayne ST, Cartmel B, Baum M, Shor-Posner G, Fallon BG, Briskin K, et al  Randomized trial of supplemental beta-carotene to prevent second head and neck cancer. Cancer Res. 2001;61:1457–1463
  82. Lippman SM, Kessler JF, Al-Sarraf M, Alberts DS, . Itri LM, Mattox D, et al.  Treatment of advanced squamous cell carcinoma of the head and neck with isotretinoin: a phase II randomized trial. Invest New Drugs. 1988;6:51–56
  83. Cascinu S, Del Ferro E, Ligi M, Graziano F, Castellani A, Catalano G. Phase II trial of 13-cis retinoic acid plus interferon-alpha in advanced squamous cell carcinoma of head and neck, refractory to chemotherapy. Ann Oncol. 1996;7:538
  84. Klaassen I, Cloos J, Smeets SJ, Brakenhoff RB, Tabor MPT, Snow GB, et al.  Non-malignant oral keratinocytes of head and neck squamous cell carcinoma patients show enhanced metabolism of retinoic acid. Oncology. 1988;2001: (in press)
  85. Gottardis MM, Bischoff ED, Shirley MA, Wagoner MA, Lamph WW, Heyman RA. Chemoprevention of mammary carcinoma by LGD1069 (Targretin) (an RXR-selective ligand). Cancer Res. 1996;56:5566–5570
  86. Miller VA, Benedetti FM, Rigas JR, Verret AL, Pfister DG, Straus D, et al.  Initial clinical trial of a selective retinoid X receptor ligand, LGD1069. J Clin Oncol. 1997;15:790–795
  87. Bischoff ED, Gottardis MM, Moon TE, Heyman RA, Lamph WW. Beyond tamoxifen (the retinoid X receptor-selective ligand LGD1069 (TARGRETIN) causes complete regression of mammary carcinoma). Cancer Res. 1998;58:479–484
  88. Van Wauwe JP, Janssen PA. Is there a case for P-450 inhibitors in cancer treatment?. J Med Chem. 1989;32:2231–2239
  89. Miller WH. The emerging role of retinoids and retinoic acid metabolism blocking agents in the treatment of cancer. Cancer. 1998;83:1471–1482
  90. Stoppie P, Borgers M, Borghgraef P, Dillen L, Goossens J, Sanz G, et al.  115866 inhibits all-trans-retinoic acid metabolism and exerts retinoidal effects in rodents. J Pharmacol Exp Ther. 2000;293:304–312
  91. Conley B, O'Shaughnessy J, Prindiville S, Lawrence J, Chow C, Jones E, et al.  Pilot trial of the safety, tolerability, and retinoid levels of N-(4-hydroxyphenyl) retinamide in combination with tamoxifen in patients at high risk for developing invasive breast cancer. J Clin Oncol. 2000;18:275–283
  92. Kurie JM, Lee JS, Khuri FR, Mao L, Morice RC, Lee JJ, et al.  N-(4-hydroxyphenyl)retinamide in the chemoprevention of squamous metaplasia and dysplasia of the bronchial epithelium. Clin Cancer Res. 2000;6:2973–2979
  93. Thaller C, Shalev M, Frolov A, Eichele G, Thompson TC, Williams RH, et al.  Fenretinide therapy in prostate cancer: effects on tissue and serum retinoid concentration. J Clin Oncol. 2000;18:3804–3808
  94. Torrisi R, Decensi A. Fenretinide and cancer prevention. Curr Oncol Rep. 2000;2:263–270
  95. Ulukaya E, Wood EJ. Fenretinide and its relation to cancer. Cancer Treat Rev. 1999;25:229–235
  96. Chen Y, Buck J, Derguini F. Anhydroretinol induces oxidative stress and cell death. Cancer Res. 1999;59:3985–3990
  97. Oridate N, Higuchi M, Suzuki S, Shroot B, Hong WK, Lotan R. Rapid induction of apoptosis in human C33A cervical carcinoma cells by the synthetic retinoid 6-[3-(1-adamantyl)hydroxyphenyl]-2-naphtalene carboxylic acid (CD437). Int J Cancer. 1997;70:484–487
  98. Shalinsky DR, Bischoff ED, Lamph WW, Zhang L, Boehm MF, Davies PJ, et al.  A novel retinoic acid receptor-selective retinoid, ALRT1550, has potent antitumor activity against human oral squamous carcinoma xenografts in nude mice. Cancer Res. 1997;57:162–168
  99. Sun SY, Yue P, Mao L, Dawson MI, Shroot B, Lamph WW, et al.  Identification of receptor-selective retinoids that are potent inhibitors of the growth of human head and neck squamous cell carcinoma cells. Clin Cancer Res. 2000;6:1563–1573
  100. Eisenhauer EA, Lippman SM, Kavanagh JJ, Parades-Espinoza M, Arnold A, Hong WK, et al.  Combination 13-cis-retinoic acid and interferon alpha-2a in the therapy of solid tumors. Leukemia. 1994;8(3):S38–S41
  101. Marth C, Daxenbichler G, Dapunt O. Synergistic antiproliferative effect of human recombinant interferons and retinoic acid in cultured breast cancer cells. J Natl Cancer Inst. 1986;77:1197–1202
  102. Fanjul AN, Bouterfa H, Dawson M, Pfahl M. Potential role for retinoic acid receptor-gamma in the inhibition of breast cancer cells by selective retinoids and interferons. Cancer Res. 1996;56:1571–1577
  103. Higashimoto Y, Ohata M, Nishio K, Iwamoto Y, Fujimoto H, Uetani K, et al.  1 alpha, 25-dihydroxyvitamin D3 and all-trans-retinoic acid inhibit the growth of a lung cancer cell line. Anticancer Res. 1996;16:2653–2659
  104. Zugmaier G, Jager R, Grage B, Gottardis MM, Havemann K, Knabbe C. Growth-inhibitory effects of vitamin D analogues and retinoids on human pancreatic cancer cells. Br J Cancer. 1996;73:1341–1346
  105. Elstner E, Linker-Israeli M, Umiel T, Le J, Grillier I, Said J, et al.  Combination of a potent 20-epi-vitamin D3 analogue (KH 1060) with 9-cis- retinoic acid irreversibly inhibits clonal growth, decreases bcl-2 expression, and induces apoptosis in HL-60 leukemic cells. Cancer Res. 1996;56:3570–3576
  106. Hong WK, Sporn MB. Recent advances in chemoprevention of cancer. Science. 1997;278:1073–1077
  107. Lippman SM, Lee JJ, Sabichi AL. Cancer chemoprevention (progress and promise). J Natl Cancer Inst. 1998;90:1514–1528

PII: S1368-8375(01)00118-X

Oral Oncology
Volume 38, Issue 6 , Pages 532-542 , September 2002

Article Tools

* Image Usage & Resolution